MedTrace Logo

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

NCT05642780 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2025-10-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.

Conditions

Interventions

DRUG

SKB264

be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;

DRUG

Pembrolizumab

be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;

Sponsors & Collaborators

  • Myriad Genetics, Inc.

    collaborator INDUSTRY

  • Discovery Life Sciences, LLC

    collaborator UNKNOWN

  • Ventana Medical Systems, Inc

    collaborator UNKNOWN

  • Frontage Laboratories, Inc.

    collaborator UNKNOWN

  • Clario

    collaborator UNKNOWN

  • Klus Pharma Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-17
Primary Completion
2027-11-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • China
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05642780 on ClinicalTrials.gov